Literature DB >> 15328094

In vitro activity of the new quinolone WCK 771 against staphylococci.

Michael R Jacobs1, Saralee Bajaksouzian, Anne Windau, Peter C Appelbaum, Mahesh V Patel, Shrikant V Gupte, Sachin S Bhagwat, Noel J De Souza, Habil F Khorakiwala.   

Abstract

The activity of WCK 771, an experimental quinolone developed to overcome quinolone resistance in staphylococci and other bacteria, was determined against quinolone-susceptible and -resistant Staphylococcus aureus and S. epidermidis. WCK 771 MICs for 50 and 90% of the strains tested (MIC(50) and MIC(90), respectively) were 0.008 and 0.015 microg/ml for S. aureus (n = 43) and 0.015 and 0.03 microg/ml for S. epidermidis (n = 44) for quinolone-susceptible isolates, compared to ciprofloxacin values of 0.12 and 0.25 microg/ml and 0.25 and 0.5 microg/ml, respectively. Values for levofloxacin were 0.12 and 0.25 microg/ml and 0.12 and 0.25 microg/ml, those for clinafloxacin were 0.015 and 0.03 microg/ml and 0.015 and 0.03 microg/ml, those for moxifloxacin were 0.03 and 0.06 microg/ml and 0.06 and 0.12 microg/ml, and those for gatifloxacin were 0.06 and 0.12 microg/ml and 0.12 and 0.25 microg/ml, respectively. The WCK 771 MIC(50) and MIC(90), respectively, were 0.5 and 1 microg/ml for both species of staphylococci (n = 73 for S. aureus, n = 70 for S. epidermidis) for isolates highly resistant to ciprofloxacin (MIC(50) and MIC(90), >32 and >32 microg/ml, respectively). Values for levofloxacin were 8 and 32 microg/ml and 8 and 32 microg/ml, those for clinafloxacin were 1 and 2 microg/ml and 0.5 and 2 microg/ml, those for moxifloxacin 4 and >4 microg/ml and 4 and >4 microg/ml, and those for gatifloxacin were 4 and >4 microg/ml and 2 and >4 microg/ml, respectively. WCK 771 and clinafloxacin demonstrated MICs of 1 microg/ml against three vancomycin-intermediate strains. WCK 771 showed concentration-independent killing for up to 24 h at 2, 4, and 8 times the MICs against quinolone-resistant staphylococci and was also bactericidal after 8 h for high-density inocula (10(8) CFU/ml) of quinolone-resistant strains at 5 microg/ml, whereas moxifloxacin at 7.5 microg/ml was bacteriostatic. WCK 771 was not a substrate of the NorA efflux pump as evident from the similar MICs against both an efflux-positive and an efflux-negative strain. Overall, WCK 771 was the most potent quinolone tested against the staphylococci tested, regardless of quinolone susceptibility.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15328094      PMCID: PMC514757          DOI: 10.1128/AAC.48.9.3338-3342.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

Review 1.  The global epidemiology of resistance to ciprofloxacin and the changing nature of antibiotic resistance: a 10 year perspective.

Authors:  C J Thomson
Journal:  J Antimicrob Chemother       Date:  1999-03       Impact factor: 5.790

2.  The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus.

Authors:  F J Schmitz; A C Fluit; M Lückefahr; B Engler; B Hofmann; J Verhoef; H P Heinz; U Hadding; M E Jones
Journal:  J Antimicrob Chemother       Date:  1998-12       Impact factor: 5.790

3.  In vitro activity of nadifloxacin against both methicillin-susceptible and -resistant clinical isolates of Staphylococcus aureus from patients with skin infections.

Authors:  S Nishijima; S Namura; H Akamatsu; S Kawai; Y Asada; S Kawabata; M Fujita
Journal:  Drugs       Date:  1995       Impact factor: 9.546

4.  Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

5.  Activity of nadifloxacin against methicillin-resistant Staphylococcus aureus isolated from skin infections: comparative study with seven other fluoroquinolones.

Authors:  S Nishijima; M Nakagawa; N Tsuboi; H Akamatsu; T Horio; M Fujita; S Kawabata
Journal:  J Int Med Res       Date:  1996 Jan-Feb       Impact factor: 1.671

6.  Sensitivity of antibacterials of Staphylococcus aureus isolated from impetigo patients.

Authors:  S Nishijima; M Nakagawa
Journal:  J Int Med Res       Date:  1997 Jul-Aug       Impact factor: 1.671

7.  Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group.

Authors:  T L Smith; M L Pearson; K R Wilcox; C Cruz; M V Lancaster; B Robinson-Dunn; F C Tenover; M J Zervos; J D Band; E White; W R Jarvis
Journal:  N Engl J Med       Date:  1999-02-18       Impact factor: 91.245

Review 8.  Fluoroquinolones: action and resistance.

Authors:  Karl Drlica; Muhammad Malik
Journal:  Curr Top Med Chem       Date:  2003       Impact factor: 3.295

9.  Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center.

Authors:  Bulent Bozdogan; Duygu Esel; Cynthia Whitener; Frederick A Browne; Peter C Appelbaum
Journal:  J Antimicrob Chemother       Date:  2003-10-16       Impact factor: 5.790

10.  Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains.

Authors:  M E Jones; M R Visser; M Klootwijk; P Heisig; J Verhoef; F J Schmitz
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

View more
  10 in total

1.  The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase.

Authors:  Sachin S Bhagwat; Lakshmi A Mundkur; Shrikant V Gupte; Mahesh V Patel; Habil F Khorakiwala
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

2.  In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.

Authors:  Sachin S Bhagwat; Pamela McGhee; Klaudia Kosowska-Shick; Mahesh V Patel; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2008-11-24       Impact factor: 5.191

3.  Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models.

Authors:  Mahesh V Patel; Noel J De Souza; Shrikant V Gupte; Mohammad A Jafri; Sachin S Bhagwat; Yati Chugh; Habil F Khorakiwala; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

Review 4.  Potential new fluoroquinolone treatments for suspected bacterial keratitis.

Authors:  Rose Herbert; Mary Caddick; Tobi Somerville; Keri McLean; Shakeel Herwitker; Timothy Neal; Gabriela Czanner; Stephen Tuft; Stephen B Kaye
Journal:  BMJ Open Ophthalmol       Date:  2022-07

5.  Levonadifloxacin, a Novel Benzoquinolizine Fluoroquinolone, Modulates Lipopolysaccharide-Induced Inflammatory Responses in Human Whole-Blood Assay and Murine Acute Lung Injury Model.

Authors:  Anasuya Patel; Ganesh V Sangle; Jinal Trivedi; Sushant A Shengule; Deepak Thorve; Mohan Patil; Nitin J Deshmukh; Bhushan Choudhari; Avinash Karade; Sangita Gupta; Sachin Bhagwat; Mahesh Patel
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

Review 6.  Emerging Treatment Options for Infections by Multidrug-Resistant Gram-Positive Microorganisms.

Authors:  Despoina Koulenti; Elena Xu; Andrew Song; Isaac Yin Sum Mok; Drosos E Karageorgopoulos; Apostolos Armaganidis; Sotirios Tsiodras; Jeffrey Lipman
Journal:  Microorganisms       Date:  2020-01-30

Review 7.  Levonadifloxacin, a Novel Broad-Spectrum Anti-MRSA Benzoquinolizine Quinolone Agent: Review of Current Evidence.

Authors:  Sachin S Bhagwat; Manohar Nandanwar; Atul Kansagara; Anusuya Patel; Swapna Takalkar; Rajesh Chavan; Hariharan Periasamy; Ravindra Yeole; Prasad K Deshpande; Satish Bhavsar; Ashima Bhatia; Jaishid Ahdal; Rishi Jain; Mahesh Patel
Journal:  Drug Des Devel Ther       Date:  2019-12-24       Impact factor: 4.162

8.  Moxifloxacin in the treatment of skin and skin structure infections.

Authors:  David Rp Guay
Journal:  Ther Clin Risk Manag       Date:  2006-12       Impact factor: 2.423

9.  Efficacy and safety of nadifloxacin for bacterial skin infections: results from clinical and post-marketing studies.

Authors:  Varsha Narayanan; Salman Motlekar; Ganesh Kadhe; Seema Bhagat
Journal:  Dermatol Ther (Heidelb)       Date:  2014-09-12

Review 10.  Antibiotics in the pipeline: a literature review (2017-2020).

Authors:  Jaffar A Al-Tawfiq; Hisham Momattin; Anfal Y Al-Ali; Khalid Eljaaly; Raghavendra Tirupathi; Mohamed Bilal Haradwala; Swetha Areti; Saad Alhumaid; Ali A Rabaan; Abbas Al Mutair; Patricia Schlagenhauf
Journal:  Infection       Date:  2021-10-04       Impact factor: 3.553

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.